1. Introduction
===============

Over the last two decades it has become increasingly clear that atherosclerosis is associated with chronic inflammation ([@bib9; @bib18; @bib22; @bib25]). While the causes of the initial insult to the artery wall remain unclear, evidence has accumulated implicating the complement system in disease progression ([@bib15; @bib17; @bib28; @bib30]). Despite these findings, studies on the role of the complement system in atherosclerosis using animal models have so far produced conflicting results ([@bib5; @bib19; @bib20; @bib24]). The deletion of C3 in apolipoprotein-E-deficient (apoE^−/−^) and C1q in low density lipoprotein receptor (ldl-r)-deficient mice caused a worsening of the disease in both cases, implying that C1q which initiates the classical pathway of complement, and C3, the central orchestrator of all complement activation pathways, have anti-atherogenic roles ([@bib5; @bib20]). In contrast a recent paper by Leung et al. looked at the effect of DAF deficiency in the ldl-r mouse model of atherosclerosis. They found a worsening of disease in the absence of DAF ([@bib12]). C5 deficiency had little or no effect in the apoE-deficient model, leading the authors to suggest that the membrane attack complex (MAC) had no role in this model of atherosclerosis ([@bib19]). Contrasting data were obtained from studies in C6-deficient rabbits which, when fed a high-fat diet, developed less atherosclerosis than their C6 sufficient controls ([@bib24]). MAC formation is blocked in both C5-deficient mice and C6-deficient rabbits, suggesting that there may be species differences in the roles of MAC in atherosclerosis; alternatively, it is possible that C5a, the other product of C5 cleavage, has a hitherto unrecognised protective role in atherosclerosis.

Regulation of the terminal pathway has also recently been examined in mice through the generation of animals deficient in CD59a, the major regulator of MAC formation in the mouse. CD59 functions by blocking the interaction of the C5b-8 complex with C9, thereby preventing the formation of the lytic membrane attack complex (MAC). These laboratories employed different models of the disease, utilising either the ldl-r or the apoE knockout mouse respectively ([@bib29; @bib31; @bib1]). Mice have two genes for CD59: Cd59a and Cd59b. Cd59a is widely expressed and the main regulator of membrane attack complex assembly in the mouse ([@bib2]), while Cd59b is highly expressed only in testis ([@bib7]). [@bib31] tested ldl-r^−/−^ mice deficient in Cd59a and showed increased plaque formation, while [@bib29] examined apoE^−/−^ mice deficient in Cd59a and Cd59b and similarly demonstrated a worsening of disease. The latter paper also showed that treatment of the triple-deficient mice while on high-fat diets with the anti-C5 monoclonal antibody BB5.1 caused a significant lessening of disease severity. This result contradicts the finding that deficiency of C5 in the apoE^−/−^ mouse did not inhibit progression of atherosclerosis ([@bib19]).

This study was initiated to clearly define the role of MAC during the development of atherosclerosis by characterising the effect of C6 deficiency on the progression of atherosclerosis in the apoE^−/−^ mouse model. We have undertaken a direct comparison of the effects of C6 and CD59a deficiency in the same colony of apoE^−/−^ mice. C6-deficient mice are particularly relevant for investigating the pathogenic roles of MAC, since they have previously been used to implicate MAC as a causative agent in a wide range of diseases, including reperfusion injury, glomerular damage, and xenograft hyperacute rejection ([@bib8; @bib10; @bib14]). ApoE deficient mice lacking C6 were markedly protected from atherosclerosis compared to C6 sufficient controls. In contrast, CD59a deficiency significantly exacerbated atherosclerosis, in agreement with recent published studies and supportive of a key role of MAC in disease progression.

2. Methods
==========

Additional methods are provided in [Supplementary material](#app1){ref-type="sec"}.

2.1. Animals
------------

Male apoE^−/−^/C6^−/−^; apoE^−/−^/Cd59a^−/−^ mice together with litter-matched controls were fed high-fat diet containing 21% (wt/wt) pork lard and supplemented with 0.15% (wt/wt) cholesterol (Special Diet Services, Witham, UK) for 8 or 12 weeks starting at 8 weeks of age. Animals were housed in a specific pathogen-free environment. All studies and protocols were approved by the institutional Ethics Review Committee and by the United Kingdom Home Office and conformed to the Guide for the Care and Use of Laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996).

2.2. Termination
----------------

Animals were anaesthetised and processed as previously described ([@bib21]). Brachiocephalic arteries were removed with a piece of the aortic arch and the stump of the right subclavian artery still attached to aid orientation during histological processing. These were immediately embedded in optimum cutting temperature (OCT) compound (Raymond A Lamb Limited, Eastbourne, UK) and snap-frozen in liquid nitrogen.

2.3. Histology and immunohistochemistry
---------------------------------------

Serial transverse sections, of 7 μm thickness, were cut along the brachiocephalic artery, starting from the proximal end. Sections were stained with Miller\'s elastin/van Gieson or oil red O (both from Sigma--Aldrich, Poole, UK). Sections were immunostained for the following complement regulators: DAF (13 μg/mL) (rat anti-mouse DAF, 2C6, prepared in-house using standard immunisation procedures) ([@bib27]); Crry (2.6 μg/mL) (rat anti-mouse Crry mAb 5D5, a generous gift from Dr. M. Holers, Denver, USA) ([@bib13]); and Cd59a (10 μg/mL) (rat anti-mouse CD59a mAb, mCD59a.7, a kind gift from Dr. C.L. Harris, Cardiff University). Macrophages, smooth muscle cells and T cells were identified using anti-murine macrophage antibody (0.1 μg/mL) (MOMA-2, Serotec, Oxford, UK), anti-α-smooth muscle actin (diluted 1:400) (clone α-1-A4; Sigma--Aldrich) and hamster anti-CD3 (20 μg/mL) (48-2B; Santa Cruz) respectively.

Immunostaining was also performed for complement components C3 (20 μg/mL) (rat anti-mouse C3 mAb 11H9; Hy-Cult Biotechnology, The Netherlands), and C9/MAC (2 μg/mL) (rabbit anti-rat C9 prepared in-house using standard immunisation procedures).

In each case positive staining was expressed as a percentage fractional area of the lesion as analysed by a computerised image-analysis program (Image ProPlus™ software version 6.3, Media Cybernetics, Carlsbad, CA, USA).

2.4. Histomorphometry
---------------------

Morphometric analyses were carried out on elastin-stained sections. One section was quantified per mouse at the same position along the brachiocephalic artery, following the established method of [@bib11]. Morphometry was performed using Image ProPlus™ software as above. The lengths of the internal and external elasticae were recorded. These were used to derive the media area by assuming them to be the circumferences of perfect circles. The plaque area was measured directly and was subtracted from the area enclosed by the internal elastic lamina to derive the true lumen area.

2.5. Serum triglyceride and cholesterol concentrations
------------------------------------------------------

Mouse blood (∼1 mL) was collected into tubes without anticoagulant, allowed to clot at room temperature and then incubated on ice for 1 h. Serum was separated by centrifugation and analysed for triglyceride, cholesterol and lipaemia index on an automated analyser (Clinical Biochemistry Laboratories, Cardiff University Hospital).

2.6. Plaque lipid content
-------------------------

Oil red O-stained sections were used to determine plaque lipid content. The total stained area in the plaque was expressed as a percentage of the total plaque area to give the fractional lipid content.

2.7. Statistical analysis
-------------------------

Data are expressed as mean ± SEM and significance tested by two-tailed unpaired Student\'s *t*-test (GraphPad Prism software version 3.0), with significance assumed at *P* \< 0.05.

3. Results
==========

3.1. Deficiency of C6 inhibits atherosclerotic plaque progression
-----------------------------------------------------------------

To delineate the role of the MAC during atherosclerosis we crossed apoE^−/−^ mice with C6^−/−^ mice generating apoE^−/−^/C6^−/−^ and litter-matched controls (apoE^−/−^/C6^+/+^). Having no C6, these mice were incapable of MAC formation from birth. The mice were fed a high-fat diet for 12 weeks to induce severe disease, in the expectation that this would amplify differences between the test and control groups. Analyses of the brachiocephalic arteries revealed that the mean plaque cross-sectional area in apoE^−/−^/C6^−/−^ mice was significantly decreased compared to the apoE^−/−^/C6^+/+^ controls. [Fig. 1](#fig1){ref-type="fig"}A and C shows representative sections from apoE^−/−^/C6^−/−^ mice while [Fig. 1](#fig1){ref-type="fig"}B and D shows representative sections from apoE^−/−^ control mice. Additionally, (C) and (D) shows the area defined as "plaque", superimposed onto the image. While [Fig. 1](#fig1){ref-type="fig"}E shows the pooled data (66.01 ± 23.2 × 10^3^ μm^2^ versus 179.5 ± 14.1 × 10^3^ μm^2^; *P* \< 0.001). [Table 1](#tbl1){ref-type="table"} summarises the morphometric analyses, including plaque, lumen, media and vessel area. The mean lumen and media areas were not different between the groups. However the total vessel area was significantly decreased in the apoE^−/−^/C6^−/−^ mice compared to apoE^−/−^ controls (349.9 ± 39.6 × 10^3^ μm^2^ versus 469.8 ± 28.2 × 10^3^ μm^2^; *P* \< 0.05). MAC deposition was abundant in plaques of control mice, both on the endothelium (inset, thick white arrow) and in the necrotic core (inset, large non-cellular area) ([Fig. 1](#fig1){ref-type="fig"}G). In contrast, no staining for MAC above background levels was found in plaques from apoE^−/−^/C6^−/−^ mice ([Fig. 1](#fig1){ref-type="fig"}F). [Fig. 1](#fig1){ref-type="fig"}H shows the pooled data for MAC deposition (apoE^−/−^/C6^−/−^: 12.8 ± 3.5% versus apoE^−/−^: 43.0 ± 6.5%; *P* ≤ 0.01). Note that the absence of MAC staining in the C6^−/−^ mice provides verification for the use of the anti-C9 antiserum as a MAC marker because these mice have normal plasma levels of C9 (data not shown).

3.2. Plaque cross-sectional area is increased in apoE/Cd59a double knockout mice
--------------------------------------------------------------------------------

To examine the role of regulation of MAC formation during atherosclerosis we generated mice deficient in both apoE and Cd59a and subjected them (together with their controls) to a period of high-fat feeding. Analysis of the brachiocephalic arteries revealed that average plaque size in apoE^−/−^/Cd59a^−/−^ mice was double that seen in gender, age, strain and litter-matched apoE^−/−^ controls on an identical diet. [Fig. 2](#fig2){ref-type="fig"}A and B shows representative sections from apoE^−/−^/Cd59a^−/−^ and apoE^−/−^ mice respectively. The pooled data are shown in [Fig. 2](#fig2){ref-type="fig"}C (59.9 ± 13.1 × 10^3^ μm^2^ versus 28.2 ± 7.9 × 10^3^ μm^2^; *P* \< 0.05). [Table 2](#tbl2){ref-type="table"} summarises the morphometric analyses, including plaque, lumen, media and vessel area. The mean lumen area, the media area and the total vessel area were not different between the groups. There were no significant differences in body weight, heart:body weight ratios, serum triglyceride or cholesterol levels, the lipaemia index, or plaque lipid content between apoE^−/−^/Cd59a^−/−^ and apoE^−/−^ mice ([supplemental data, Table 1 and Fig. 1](#app1){ref-type="sec"}).

3.3. CD59a deficiency causes increased deposition of MAC in plaques
-------------------------------------------------------------------

The extent of terminal complement pathway activation was examined by staining for C9 deposition as a surrogate marker of MAC (verified as described above). Complement activation was also assessed by staining for C3 fragment deposition. MAC staining was absent from unaffected vessel walls (i.e. those with no plaque), but clearly present in early and late stage plaques obtained from both apoE^−/−^/Cd59a^−/−^ ([Fig. 3](#fig3){ref-type="fig"}A) and apoE^−/−^ mice ([Fig. 3](#fig3){ref-type="fig"}B). To better visualise and analyse the expected increase in MAC staining in apoE^−/−^/Cd59a^−/−^ mice, fluorescence intensity detection limits were set at a high sensitivity level, hence the apparently low levels of MAC staining recorded in apoE controls. MAC deposits were more than 10-fold increased in the apoE^−/−^/Cd59a^−/−^ mice compared to the apoE^−/−^ controls ([Fig. 3](#fig3){ref-type="fig"}C; 28.9 ± 9.4% versus 2.7 ± 0.8%; *P* ≤ 0.05). C3 deposition was detected weakly in unaffected artery walls and strongly in plaques from the brachiocephalic arteries of both apoE^−/−^/Cd59a^−/−^ and apoE^−/−^ mice ([Fig. 3](#fig3){ref-type="fig"}D and E, respectively). There was no significant difference in levels of C3 between the apoE^−/−^/Cd59a^−/−^ mice and their apoE^−/−^ controls ([Fig. 3](#fig3){ref-type="fig"}F). To assess whether increased MAC deposition in apoE^−/−^/Cd59a^−/−^ mice would cause an increase in the numbers of inflammatory cells within the plaque we stained for macrophages and T cells. There were no significant differences in the proportions of plaque area staining for macrophages or T cells (as revealed by staining with MOMA-2 and CD3, respectively) between the two groups ([Supplemental Data Figs. 2 and 3](#app1){ref-type="sec"}).

3.4. Absence of CD59a is not compensated by up-regulation of other complement regulators
----------------------------------------------------------------------------------------

The membrane-bound complement regulators Crry and decay accelerating factor (DAF) were expressed in normal vessel walls and plaques in both groups of mice ([Fig. 4](#fig4){ref-type="fig"}A, B, D and E). There was no gross difference in the pattern or abundance of expression of either Crry or DAF between the groups. Cd59a expression was absent from apoE^−/−^/Cd59a^−/−^ mice and present within the brachiocephalic arteries of apoE^−/−^ mice ([Fig. 4](#fig4){ref-type="fig"}C and F, respectively).

3.5. In the absence of CD59a the MAC influences smooth muscle cell proliferation and survival in atherosclerosis
----------------------------------------------------------------------------------------------------------------

Because of the known effect that the MAC has on smooth muscle cell proliferation ([@bib3]) we decided to quantify smooth muscle cell content by staining for α-actin in plaques from the brachiocephalic arteries of apoE^−/−^mice lacking the MAC regulator CD59a. Grouping the plaques into "early" (fatty streaks and fibrous plaques with cross-sectional areas \<80 × 10^3^ μm^2^) and "advanced" (complex plaques with cross-sectional areas ≥80 × 10^3^ μm^2^) we found a significant increase in the smooth muscle cell content of "early" plaques from apoE^−/−^/Cd59a^−/−^ mice as compared to apoE^−/−^mice (% α-actin staining 62.0% ± 7.1% versus 21.4 ± 6.1%; *P* \< 0.01). [Fig. 5](#fig5){ref-type="fig"}A and B shows representative pictures of early plaques stained for smooth muscle cell α-actin. By contrast, in "advanced" plaques smooth muscle cell content was significantly reduced in the plaques from apoE^−/−^/Cd59a^−/−^ mice versus apoE^−/−^ controls (% α-actin staining 15.3 ± 4.8% versus 36.6 ± 6.7%; *P* \< 0.05). [Fig. 5](#fig5){ref-type="fig"}C and D shows representative pictures of advanced plaques stained for smooth muscle cell α-actin. Combined data are presented in [Fig. 5](#fig5){ref-type="fig"}E. The proportion of plaque staining for α-actin in the apoE^−/−^/Cd59a^−/−^ mice fell more than three-fold between "early" and "advanced" plaques (62.0% ± 7.1% versus 15.3 ± 4.8%; *P* \< 0.01). [Fig. 5](#fig5){ref-type="fig"}F--I shows C9 deposition in smooth muscle cell regions of an atherosclerotic plaque from an apoE deficient mouse.

4. Discussion
=============

In this paper we set out to unequivocally define the roles of the MAC in atherosclerotic plaque formation in the apoE^−/−^ mouse model. Importantly, we clearly show, for the first time, that deficiency of C6 is strongly protective against progression of atherosclerosis in apoE^−/−^ mice. This result is consistent with published studies in fat fed C6-deficient rabbits and strongly implicates the MAC in both of these models of atherosclerosis ([@bib24]). Secondly, we tested the effects of deficiency of the major murine regulator of MAC formation, CD59a, and showed that apoE^−/−^/Cd59a^−/−^ mice developed much larger plaques on fat feeding when compared to closely matched apoE^−/−^ controls; MAC deposition in the plaques was also markedly increased in apoE^−/−^/Cd59a^−/−^ mice. Of note we have also shown in these mice that the smooth muscle cell content of advanced plaques is significantly less than that seen in apoE^−/−^ controls. This finding suggests a possible mechanism whereby MAC formation could contribute not only to plaque development but also to plaque instability and hence the incidence of vessel rupture and consequent acute infarcts or strokes.

The data that we have presented here on the contrasting effects of C6 and CD59a deficiency on plaque development in apoE^−/−^ mice clearly support the hypothesis that the MAC is an important contributor to atherosclerotic plaque development in the apoE^−/−^ mouse model. In fat fed apoE^−/−^/C6^−/−^ mice, plaque size was markedly reduced and staining for MAC deposition within the plaques was also significantly reduced; the converse was true in apoE^−/−^/Cd59a^−/−^ mice with much larger plaques compared to controls and increased MAC deposition. The mean total vessel area in apoE^−/−^/C6^−/−^ mice was significantly smaller than that seen in apoE^−/−^ controls, while the lumen area remained the same between the two groups. This is due to arterial remodelling which occurs during atherosclerosis and maintains the lumen area in the face of increased obstruction caused by plaque growth. The extent of disease in these mice correlated with the extent of MAC deposition. In contrast to the markedly elevated MAC deposition, C3 staining was seen strongly in plaques from both apoE^−/−^/Cd59a^−/−^ and apoE^−/−^ controls, an observation which has been previously noted ([@bib1]). Most of the MAC deposited in the plaques is associated with extracellular debris and lipid, which accumulate in the core of advanced plaques. Activation of complement at this location is probably due to the presence of oxidised and enzymatically modified LDL, known to activate complement through the alternative pathway ([@bib4]). Of note, the expression of the other broadly expressed murine membrane complement regulators DAF and Crry was not different between the two groups, indicating that deficiency of CD59a was not compensated by increased expression of other regulators. Plaque lipid content and macrophage and T cell infiltration were also similar in test and control groups.

Smooth muscle cell proliferation is a characteristic feature of plaque formation. In small, simple plaques from apoE^−/−^/Cd59a^−/−^ mice, smooth muscle cell accumulation was markedly increased compared to apoE^−/−^ controls, suggesting accelerated plaque development. In addition we observed an association between C9 deposition and regions of smooth muscle cell within atherosclerotic plaques. The MAC has previously been shown to cause aortic smooth muscle cell proliferation in vitro ([@bib16]), which strengthens our impression that this is a MAC triggered event. In contrast, larger and more advanced plaques in apoE^−/−^/Cd59a^−/−^ mice contained fewer smooth muscle cells than similar sized plaques from apoE^−/−^ controls, likely due to MAC-induced cytolysis. Reduced smooth muscle cell number in these late plaques in apoE^−/−^/Cd59a^−/−^ mice will render the plaques unstable and vulnerable to rupture. These observations are compatible with those of [@bib29] who noted that the plaques present in their apoE^−/−^/Cd59a^−/−^/Cd59b^−/−^ mice had a more vulnerable phenotype than those of the apoE^−/−^ controls.

MAC deposition is a characteristic feature of human atherosclerotic lesions; the pattern of MAC deposition in murine plaques closely resembles that seen in humans ([@bib23]). It is therefore reasonable to propose that MAC contributes to plaque formation and progression in human atherosclerosis in a similar manner to that which we and others have now demonstrated occurs in mice. Our data are in agreement with Wu et al., who also implicated the terminal pathway in the progression of atherosclerosis. More recently, [@bib12] have shown that DAF deficiency exacerbates disease in the ldl-r mouse model of atherosclerosis again implying that unregulated complement activation accelerates the progression if atherosclerosis. However, these findings are at odds with a previous study which had showed no effect of terminal pathway disruption (at the level of C5) on the progression of atherosclerosis in fat fed apoE^−/−^ mice ([@bib19]). These contrasting findings highlight the need for further investigation into the role of C5 and C6 in atherosclerosis.

Inhibition of MAC formation is a potential strategy for therapy of atherosclerosis and a realistic one given that terminal pathway inhibitors are already in use in the clinic ([@bib6]), with more under development ([@bib26]).
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![Analysis of atherosclerosis in apoE^−/−^/C6^−/−^ mice. Plaque area measurement in brachiocephalic arteries of apoE^−/−^/C6^−/−^ and apoE^−/−^ mice fed a high-fat diet from 8 weeks of age for 12 weeks. Sections of the brachiocephalic artery were stained with Miller\'s elastin/van Gieson. The bars show group means ± SEM. Scale bars: 200 μm unless otherwise stated. (A and C) Small plaques (arrowed) from the brachiocephalic arteries of apoE^−/−^/C6^−/−^ mice. (C) Area defined as plaque using Image ProPlus™ software. (B and D) Large plaques from the brachiocephalic arteries of apoE^−/−^ mice. (D) Area defined as plaque using Image ProPlus™ software. (E) Mean plaque area in apoE^−/−^/C6^−/−^ and apoE^−/−^ mice. Brachiocephalic artery sections were stained with rabbit anti-rat C9 (red) for MAC deposition and nuclei were stained blue with DAPI. (F) Minimal C9 staining in a large plaque from an apoE^−/−^/C6^−/−^ mouse. (G) MAC staining is abundant in an advanced plaque of an apoE^−/−^ mouse. Insets show higher magnification of areas where C9 deposition is localised within the plaque: lining the endothelial wall (arrowed) and within the necrotic core of the plaque (inset scale bar: 50 μm). (H) Comparison of percentage membrane attack complex staining in apoE^−/−^/C6^−/−^ and apoE^−/−^ mice.](gr1){#fig1}

![Plaque area measurement in brachiocephalic arteries of apoE^−/−^/Cd59a^−/−^ and apoE^−/−^ control mice after 8 weeks of high-fat feeding. Sections of the brachiocephalic artery were stained with Miller\'s elastin/van Gieson. The bars show group means ± SEM. Scale bars: 200 μm. (A) Single large plaque occupying half of the vessel from an apoE^−/−^/Cd59a^−/−^ mouse. (B) A small plaque (arrowed) from an apoE^−/−^ mouse. (C) Mean plaque area in apoE^−/−^/Cd59a^−/−^ and apoE^−/−^ mice.](gr2){#fig2}

![MAC deposition and lesional C3 levels in atherosclerotic brachiocephalic arteries. Comparison of percentage MAC staining (panels A--C) or C3 staining (panels D--F) in apoE^−/−^Cd59a^−/−^ and apoE^−/−^ animals at 16 weeks after 8 weeks of high-fat diet. Sections of the brachiocephalic artery were stained with rabbit anti-rat C9 for MAC or rat anti-mouse C3 (red) and nuclei were stained with DAPI (blue). The bars show group means ± SEM. Scale bars: 200 μm. (A) Representative section from an apoE^−/−^/Cd59a^−/−^ mouse. (B) Representative section from an apoE^−/−^ mouse. (C) Mean percentage of lesional MAC staining in apoE^−/−^/Cd59a^−/−^ and apoE^−/−^ mice. (D) Representative section from apoE^−/−^/Cd59a^−/−^ mouse. (E) Representative section from apoE^−/−^ mouse. (F) Mean percentage of lesional C3 staining in apoE^−/−^/Cd59a^−/−^ and apoE^−/−^ mice.](gr3){#fig3}

![Immunolocalisation of complement regulators. apoE/Cd59a and apoE deficient mice were fed a high-fat diet for 8 weeks from 8 weeks of age. Sections of the brachiocephalic artery were stained for complement regulators using specific monoclonal antibodies (brown) and nuclei were stained with haematoxylin (blue). Scale bars: 50 μm. Lumen is indicated by L. (A--C) Staining of Crry (rat anti-mouse Crry mAb (5D5)), decay accelerating-factor (DAF) (2C6) and Cd59a respectively in apoE^−/−^/Cd59a^−/−^ mice. (D--F) Staining of Crry, DAF and Cd59a respectively in apoE^−/−^ mice.](gr4){#fig4}

![Smooth muscle cell content in early and advanced lesions. Comparison of percentage smooth muscle α-actin staining in early plaques (\<80 × 10^3^ μm^2^) or advanced plaques (complex plaques with areas ≥80 × 10^3^ μm^2^) of apoE^−/−^/Cd59a^−/−^ and apoE^−/−^ animals at 16 weeks, after 8 weeks of high-fat diet. Brachiocephalic artery sections were stained for smooth muscle cells with anti-smooth muscle α-actin and counterstained with haematoxylin (blue). The bars show group means ± SEM. Scale bars for (A--D): 200 μm. (A) Representative section of an early lesion from an apoE^−/−^/Cd59a^−/−^ mouse. (B) Representative section of an early lesion from an apoE^−/−^ control. (C) Representative section of an advanced lesion from an apoE^−/−^/Cd59a^−/−^ mouse. (D) Representative section of an advanced lesion from an apoE^−/−^ control. (E) Percentage of plaque stained for smooth muscle α-actin in early and advanced plaques of apoE^−/−^/Cd59a^−/−^ and apoE^−/−^ mice. (F--I) An atherosclerotic vessel from an apoE deficient mouse showing C9 deposition co-localised in regions of smooth muscle cells. Images show cell nuclei (blue), C9 (red) or smooth muscle α-actin (green) (F--H respectively). (I) Merged images correspond to the overlay of cell nuclei, C9 and smooth muscle α-actin ([Fig. 1](#fig1){ref-type="fig"}). Co-localisation of C9 with smooth muscle α-actin is shown in yellow. Scale bar = 100 μm.](gr5){#fig5}

###### 

Brachiocephalic artery morphometric data in 20-week-old apoE^−/−^/C6^−/−^ and apoE^−/−^ mice.

  Group                         Vessel area (×10^3^ μm^2^)                        Plaque area (×10^3^ μm^2^)                            Media area (×10^3^ μm^2^)   Lumen area (×10^3^ μm^2^)
  ----------------------------- ------------------------------------------------- ----------------------------------------------------- --------------------------- ---------------------------
  apoE^−/−^/C6^−/−^ (*n* = 8)   [\*](#tbl1fn1){ref-type="table-fn"}349.9 ± 39.6   [\*\*\*](#tbl1fn2){ref-type="table-fn"}66.01 ± 23.2   100.2 ± 11.7                183.7 ± 15.9
  apoE^−/−^ (*n* = 10)          469.8 ± 28.2                                      179.5 ± 14.1                                          97.5 ± 10.1                 192.8 ± 17.2

All animals were fed a high-fat diet from 8 weeks of age for 12 weeks.

*P* \< 0.05 versus apoE^−/−^ control.

*P* \< 0.001 versus apoE^−/−^ control.

###### 

Brachiocephalic artery morphometric data in 16-week-old apoE^−/−^/Cd59a^−/−^ and apoE^−/−^ mice.

  Group                             Vessel area (×10^3^ μm^2^)   Plaque area (×10^3^ μm^2^)                       Media area (×10^3^ μm^2^)   Lumen area (×10^3^ μm^2^)
  --------------------------------- ---------------------------- ------------------------------------------------ --------------------------- ---------------------------
  apoE^−/−^/Cd59a^−/−^ (*n* = 14)   345.0 ± 25.0                 [\*](#tbl2fn1){ref-type="table-fn"}59.9 ± 13.1   97.0 ± 7.6                  188.0 ± 10.8
  apoE^−/−^ (*n* = 15)              325.0 ± 20.0                 28.2 ± 7.9                                       90.0 ± 8.1                  207.0 ± 9.8

All animals were fed a high-fat diet from 8 weeks of age for 8 weeks.

*P* \< 0.05 versus apoE^−/−^ control.
